# Molecular Triaging of Newly Diagnosed Breast Cancer

> **NCT01159236** · NA · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Fluorouracil
- **DRUG:** Doxorubicin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01159236
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recent developments lead to re-evaluation of study.
- **Last updated:** 2012-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159236, "Molecular Triaging of Newly Diagnosed Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01159236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*